Evidence map›Paper›PMID 35546241›Full record

ArticleJournal of hematology & oncology2022

Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis.

Junjie Huang, Wing Sze Pang, Veeleah Lok, Lin Zhang, Don Eliseo Lucero-Prisno, Wanghong Xu, Zhi-Jie Zheng, Edmar Elcarte, Mellissa Withers, Martin C S Wong and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06563245 (A Phase II/III Study of Brentuximab Vedotin for Newly Diagnosed Classical Hodgkin Lymphoma in Chinese CAYA Based on PET/CT Assessment), which is not on this map. Cited by 84 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 7 pooled it
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06563245 phase2 / phase3recruitingnot on this mapstarted 2024, after this paper: background citation

A Phase II/III Study of Brentuximab Vedotin for Newly Diagnosed Classical Hodgkin Lymphoma in Chinese CAYA Based on PET/CT Assessment

TypeinterventionalSponsorChildren's Cancer Group, ChinaRan2024 to 2039Enrolled96ConditionsClassical Hodgkin Lymphoma, Child, Adolescent, Young AdultArmsBrentuximab Vedotin for Injection, response-adapted radiation, Doxorubicin, Etoposide, Prednisone
3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 7 syntheses or guidelines pooled it, 128 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 6 countries.

Junjie HuangThe Jockey Club School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong, Room 407, 4/F, Postgraduate Education Centre, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, NT, Hong Kong SAR, China.
Wing Sze PangThe Jockey Club School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong, Room 407, 4/F, Postgraduate Education Centre, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, NT, Hong Kong SAR, China.
Veeleah LokDepartment of Global Public Health, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
Lin ZhangSchool of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
Don Eliseo Lucero-PrisnoDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.
Wanghong XuSchool of Public Health, Fudan University, Shanghai, China.
Zhi-Jie ZhengDepartment of Global Health, School of Public Health, Peking University, Beijing, China.
Edmar ElcarteUniversity of the Philippines, Manila, The Philippines.
Mellissa WithersDepartment of Population and Health Sciences, USC Institute On Inequalities in Global Health, APRU Global Health Program, Keck School of Medicine of USC, University of Southern California, Soto Street Building, SSB318G, 2001 North Soto Street, MC 9239, Los Angeles, CA, 90089-9239, USA. mwithers@usc.edu.
Martin C S WongThe Jockey Club School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong, Room 407, 4/F, Postgraduate Education Centre, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, NT, Hong Kong SAR, China. wong_martin@cuhk.edu.hk.
NCD Global Health Research Group, Association of Pacific Rim Universities (APRU)
Peking University · CNChinese University of Hong Kong · CNFudan University · CNHong Kong Jockey Club · CNKarolinska University Hospital · SELondon School of Hygiene & Tropical Medicine · GBUniversity of Melbourne · AUUniversity of Southern California · USUniversity of the Philippines Manila · PH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHodgkin lymphoma is a lymphatic malignancy commonly found in cervical lymph nodes. This study evaluated the worldwide incidence, mortality, associated risk factors, and temporal trends of Hodgkin lymphoma by sex, age, and country.

methodsThe age-standardised Hodgkin lymphoma incidence and mortality were retrieved from the GLOBOCAN, CI5 volumes I-XI, WHO mortality database, the NORDCAN and SEER Program. The age-standardised prevalence of smoking, alcohol drinking, obesity, and hypertension was also extracted for each country. Trends were tested using Average Annual Percentage Change (AAPC) from Joinpoint regression analysis.

resultsThe Hodgkin lymphoma incidence and mortality were 0.98 and 0.26 per 100,000 in 2020. A higher incidence was observed in high-income countries, while higher mortality was found in low-income countries. Incidence and mortality were associated with GDP per capita, prevalence of smoking, obesity, and hypertension at the population level. Despite the decreasing mortality trend, there was an increasing incidence, especially among females, younger population, and subjects from Asian countries.

conclusionsThere was an increasing trend in Hodgkin lymphoma incidence, especially among subjects who were female, younger population, and from Asian countries. Further studies are needed to investigate the reasons for these epidemiologic trends.

Indexed as

Hodgkin DiseaseHypertensionData AnalysisFemaleGlobal HealthHumansIncidenceMaleObesityRisk FactorsHodgkin lymphomaIncidenceMortalityRisk factorsTemporal trend

Identifiers

PMID35546241
PMCPMC9097358
OpenAlexW4280555363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.